0000899243-20-035444.txt : 20201229
0000899243-20-035444.hdr.sgml : 20201229
20201229211453
ACCESSION NUMBER: 0000899243-20-035444
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201228
FILED AS OF DATE: 20201229
DATE AS OF CHANGE: 20201229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turtle Cameron
CENTRAL INDEX KEY: 0001758363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 201423828
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-28
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001758363
Turtle Cameron
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
0
1
0
0
See Remarks
Common Stock
2020-12-28
4
M
0
7500
17.00
A
20068
D
Common Stock
2020-12-28
4
M
0
6000
0.34
A
26068
D
Common Stock
2020-12-28
4
M
0
6000
0.16
A
32068
D
Common Stock
2020-12-28
4
S
0
10937
69.3361
D
21131
D
Common Stock
2020-12-28
4
S
0
8563
69.9352
D
12568
D
Stock Option (Right to Buy)
17.00
2020-12-28
4
M
0
7500
0.00
D
2029-06-26
Common Stock
7500
255500
D
Stock Option (Right to Buy)
0.34
2020-12-28
4
M
0
6000
0.00
D
2020-05-19
2029-07-14
Common Stock
6000
31766
D
Stock Option (Right to Buy)
0.16
2020-12-28
4
M
0
6000
0.00
D
2020-05-19
2029-05-23
Common Stock
6000
56042
D
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020.
Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share.
The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Senior Vice President, Portfolio Management and Corporate Development
/s/ Tara Condon, Attorney-in-Fact
2020-12-29